At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 306 enrolled
Drug / intervention
Tafenoquine +2 moredrug
Likely dose
Tafenoquine 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled Evaluation of Weekly Tafenoquine (WR 238605/SB252263) Compared to Mefloquine for Chemosuppression of Plasmodium Falciparum in Western Kenya
U.S. Army Medical Research and Development Command·interventional·Posted Jul 2, 2015·Updated May 30, 2017
In Brief
A Phase 2 clinical trial evaluating Tafenoquine, Mefloquine, and 1 other intervention for Falciparum Parasitaemia. Completed, enrolled 306 participants.
Detailed Summary
This was a placebo controlled, randomised, double-blind, double-dummy study of the efficacy of weekly tafenoquine compared with weekly mefloquine or placebo in the chemosuppression of P. falciparum in Nyanza Province, western Kenya.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFalciparum Parasitaemia
Countries--
CollaboratorsSmithKline Beecham
Timeline
Phase 2CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2000
Primary CompletionOct 2000
Study CompletionMar 2003
First PostedJul 2015
TodayJul 2026
First PostedJul 2, 2015
Enrollment StartMay 1, 2000
Primary CompletionOct 1, 2000
Study CompletionMar 1, 2003
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11 years ago
Interventions
Tafenoquinedrug
Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
Mefloquinedrug
Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
Placebodrug
Placebo for three days followed by placebo once a week for 24 weeks